Unknown

Dataset Information

0

Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study.


ABSTRACT: BACKGROUND:The World Health Organization (WHO) recommendation of treating uncomplicated malaria during the second and third trimester of pregnancy with an artemisinin-based combination therapy (ACT) has already been implemented by all sub-Saharan African countries. However, there is limited knowledge on the effect of ACT on pregnancy outcomes, and on newborn and infant's health. METHODS:Pregnant women with malaria in four countries (Burkina Faso, Ghana, Malawi and Zambia) were treated with either artemether-lumefantrine (AL), amodiaquine-artesunate (ASAQ), mefloquine-artesunate (MQAS), or dihydroartemisinin-piperaquine (DHA-PQ); 3127 live new-borns (822 in the AL, 775 in the ASAQ, 765 in the MQAS and 765 in the DHAPQ arms) were followed-up until their first birthday. RESULTS:Prevalence of placental malaria and low birth weight were 28.0% (738/2646) and 16.0% (480/2999), respectively, with no significant differences between treatment arms. No differences in congenital malformations (p = 0.35), perinatal mortality (p = 0.77), neonatal mortality (p = 0.21), and infant mortality (p = 0.96) were found. CONCLUSIONS:Outcome of pregnancy and infant survival were similar between treatment arms indicating that any of the four artemisinin-based combinations could be safely used during the second and third trimester of pregnancy without any adverse effect on the baby. Nevertheless, smaller safety differences between artemisinin-based combinations cannot be excluded; country-wide post-marketing surveillance would be very helpful to confirm such findings. Trial registration ClinicalTrials.gov, NCT00852423, Registered on 27 February 2009, https://clinicaltrials.gov/ct2/show/NCT00852423.

SUBMITTER: Nambozi M 

PROVIDER: S-EPMC6437904 | BioStudies | 2019-01-01

SECONDARY ACCESSION(S): NCT00852423

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5434531 | BioStudies
2020-01-01 | S-EPMC7264303 | BioStudies
1000-01-01 | S-EPMC3346948 | BioStudies
2013-01-01 | S-EPMC3552837 | BioStudies
2019-01-01 | S-EPMC6990969 | BioStudies
2014-01-01 | S-EPMC4249977 | BioStudies
1000-01-01 | S-EPMC5883595 | BioStudies
2020-01-01 | S-EPMC6945612 | BioStudies
2009-01-01 | S-EPMC2698916 | BioStudies
2020-01-01 | S-EPMC7263905 | BioStudies